Extracellular matrix provides structural and biochemical support to surrounding cells. It consists of structural proteins such as collagen, elastin as well as specialized proteins such as fibronectin and proteoglycans. Extracellular matrices are used in tissue regeneration, drug discovery, cell cultures and other medical applications. ECM products are used as scaffolds to support cell proliferation and tissue regeneration in wound repair, tissue engineering applications and surgical reconstruction procedures.
The global extracellular matrix market is estimated to be valued at US$1.4 billion in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
There has been an increase in demand for ECM products in wound care and soft tissue regeneration applications owing to increasing prevalence of chronic wounds and soft tissue injuries. According to International Diabetes Federation, the number of people suffering from diabetes is expected to increase to 642 million by 2040 from 463 million in 2019 globally. Diabetic foot ulcers are a major complication of diabetes and their treatment involves use of ECM products. Similarly, increasing incidence of traumatic injuries and sports injuries is contributing to demand for ECM in soft tissue reconstruction. Ongoing research to derive ECM products from new sources such as amniotic membrane and small intestinal submucosa is also expected to aid market growth over the forecast period. Developments aimed at enhancing efficacy of ECM products through modifications involving recombinant proteins and growth factors will further support market expansion through 2031.
Porter’s Analysis
Threat of new entrants: Low. It requires high capital investment and technology to enter this market due to stringent regulatory policies.
Bargaining power of buyers: Moderate. The presence of alternative options increases the bargaining power of buyers.
Bargaining power of suppliers: High. Raw materials such as hyaluronic acid, collagen, proteoglycans have limited suppliers in the market which increases their bargaining power.
Threat of new substitutes: Moderate. Emerging biomaterial-based alternatives pose moderate threat of substitution.
Competitive rivalry: High. The market consists of global key players intensifying competition through product launches and strategic partnerships.
Key Takeaways
The Global Extracellular Matrix Market Size is estimated to be valued at US$1.4 billion in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024 to 2031.
North America is projected to dominate the market during the forecast period owing to the increasing adoption of regenerative medicines and rising investment in R&D activities within the region. The Asia Pacific region is poised to grow at the fastest CAGR during the forecast period. This is attributed to growing healthcare industry, rising medical tourism, and increasing expenditure on healthcare within emerging economies like India and China in the region.
Key players analysis comprises- Key players operating in the extracellular matrix market are Abbott, Medtronic, Boston Scientific Corporation, Edwards Lifesciences Corporation, Baxter, Johnson & Johnson, Becton, Dickinson and Company. CryoLife operated in the heart valves segment and distributed cardiac and vascular surgical products. Stryker focuses on surgical tools and orthopaedic implants.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it